Zavamet SR 500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. This complementary mechanism of action helps achieve better glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Zavamet SR 500 is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient. The sustained-release formulation allows for once or twice-daily dosing, improving patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, with a low risk of hypoglycemia due to the glucose-dependent action of Vildagliptin. Regular monitoring of renal function is recommended due to Metformin’s renal clearance. Zavamet SR 500 should be used cautiously in patients with renal impairment, hepatic dysfunction, or heart failure. This combination therapy offers an effective and convenient option for optimizing glycemic control in type 2 diabetes management.